| Assessment Status | Rapid Review Complete |
| HTA ID | 23004 |
| Drug | Ropeginterferon alfa-2b |
| Brand | Besremi® |
| Indication | Ropeginterferon alfa-2b is indicated as monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly. |
| Assessment Process | |
| Rapid review commissioned | 20/01/2023 |
| Rapid review completed | 15/03/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ropeginterferon alfa-2b compared with the current standard of care. |
